• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Anaerobe . The burden of Clostridioides difficile infection in COVID-19 patients: A systematic review and meta-analysis

tetano

Editor, Senior Moderator
Anaerobe


. 2021 Nov 26;102484.
doi: 10.1016/j.anaerobe.2021.102484. Online ahead of print.
The burden of Clostridioides difficile infection in COVID-19 patients: A systematic review and meta-analysis


Guido Granata[SUP] 1 [/SUP], Nicola Petrosillo[SUP] 2 [/SUP], Samir Al Moghazi[SUP] 1 [/SUP], Emanuela Caraffa[SUP] 1 [/SUP], Vincenzo Puro[SUP] 3 [/SUP], Glenn Tillotson[SUP] 4 [/SUP], Maria Adriana Cataldo[SUP] 3 [/SUP]



Affiliations

Abstract

Objectives: The main aim of this systematic review and meta-analysis was to assess the proportion of confirmed COVID-19 patients with Clostridioides difficile infection (CDI) and to describe risk factors and outcome of these patients.
Methods: MEDLINE and Cochrane Central Register of Controlled Trials databases were searched up to 15 July 2021. We included studies reporting data on CDI occurring in patients with a confirmed diagnosis of COVID-19. We pooled proportion of CDI patients using a random effects model (DerSimonian-Laird method) stabilising the variances using the Freeman-Tukey double arcsine transformation.
Results: Thirteen studies were included in the systematic review. All the studies retrospectively collected data between February 2020 and February 2021. The reported CDI incidence rates ranged from 1.4 to 4.4 CDI cases per 10,000 patient-days. Seven studies reported data on the number of COVID-19 patients who developed CDI and the total number of COVID-19 patients in the study period and were included in the meta-analysis, comprising 23,697 COVID-19 patients. The overall pooled proportion of COVID-19 patients who had CDI was 1% [95% confidence interval: 1-2]. Among studies reporting CDI occurrence in patients with and without COVID-19, the majority of them reported reduced or unchanged CDI rates compared to pre-COVID period.
Conclusions: CDI is a relevant issue for COVID-19 patients. Adherence to infection prevention and control measures and to the antimicrobial stewardship principles is crucial even during the COVID-19 pandemic.

Keywords: Antibiotic use; CDI prevalence; Clostridioides difficile infection; Coronavirus disease 2019 pandemic; Infection control measures; Meta analysis; Risk factors.
 
Back
Top Bottom